Related Experiment Video
Updated: Jul 16, 2026
Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
Published on: March 1, 2016
[Cell therapies in cardiology: results from the first randomized clinical trials]
G Vassalli1, P Gersbach, E Ferrari
1Service de cardiologie, CHUV, Lausanne. giuseppe.vassalli@chuv.ch
Insights
Bone marrow cell transplantation after heart attack shows mixed results in preventing cardiac remodeling. While some studies indicate modest benefits, further research is needed to optimize this cell therapy for heart disease.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Stem Cell Therapy
Context:
- Acute myocardial infarction leads to cardiac tissue scarring and ventricular remodeling, often resulting in heart failure.
- Autologous bone marrow-derived cells are explored as a therapeutic strategy to mitigate post-infarct cardiac damage.
- Previous clinical trials have yielded inconsistent outcomes regarding the efficacy of this intervention.
Purpose:
- To evaluate the effectiveness of early post-infarct transplantation of autologous bone marrow-derived cells in preventing ventricular remodeling.
- To assess the impact of bone marrow cell transplantation on ventricular function in patients with acute myocardial infarction and chronic ischemic heart disease.
Summary:
- Four randomized clinical trials investigating bone marrow cell transplantation post-myocardial infarction reported mixed results.
- One trial showed transient improvement in ventricular function; another indicated a modest, time-limited benefit.
- Two trials yielded negative results, highlighting the need for further investigation and optimization of cell therapy protocols.
Impact:
- Bone marrow cell transplantation shows potential but remains an early-stage therapy for heart disease, requiring significant improvement.
- Findings underscore the variability in outcomes and the need for refined strategies in cardiac cell-based regenerative medicine.
- Further research is crucial to determine optimal cell types, delivery methods, and patient selection for cardiac repair.
Abstract:
Following acute myocardial infarction, necrotic cardiac tissue is replaced by scar leading to ventricular remodeling and pump failure. Transplantation of autologous bone marrow-derived cells into the heart, early post-infarct, aims to prevent ventricular remodeling. This strategy has been evaluated in four controlled, randomized clinical trials, which provided mixed results. A transient improvement in ventricular function was observed in one trial, and a modest improvement (the duration of which remains to be determined) in an additional trial, whereas two trials showed negative results. A modest benefit of bone marrow cell transplantation was also observed in patients with chronic ischemic heart disease. Despite mixed results reported so far, cell therapy of heart disease still is in its infancy and has considerable room for improvement.
